Neoleukin Therapeutics Inc Forecast, price target & analysts
Neoleukin Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Neoleukin Therapeutics Inc Classifications & Recommendation:
Neoleukin Therapeutics Inc Price Target
| Target Price | $52.80 |
| Price | $17.10 |
| Potential |
208.77%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Neoleukin Therapeutics Inc 2026 .
The average Neoleukin Therapeutics Inc target price is $52.80.
This is
208.77%
register free of charge
$72.00
321.05%
register free of charge
$45.00
163.16%
register free of charge
|
|
| A rating was issued by 7 analysts: 7 Analysts recommend Neoleukin Therapeutics Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Neoleukin Therapeutics Inc stock has an average upside potential 2026 of
208.77%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 0.91 |
5 Analysts have issued a sales forecast Neoleukin Therapeutics Inc 2024 . The average Neoleukin Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast Neoleukin Therapeutics Inc 2024 . The average Neoleukin Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.83 | -3.69 |
| 34.19% | 30.39% | |
| P/E | negative | |
| EV/Sales | 257.33 |
1 Analysts have issued a Neoleukin Therapeutics Inc forecast for earnings per share. The average Neoleukin Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Neoleukin Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 250.41 | |
|---|---|---|
| 2024 |
257.33
2.76%
Unlock
|
|
P/S ratio
| Current | ||
|---|---|---|
| 2024 |
396.41
2.76%
Unlock
|
|
Neoleukin Therapeutics Inc...
Current Neoleukin Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 25 2024 |
| BMO Capital | Locked ➜ Locked | Locked | Nov 20 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 19 2024 |
| Baird | Locked ➜ Locked | Locked | Nov 12 2024 |
| BMO Capital | Locked ➜ Locked | Locked | Nov 12 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 12 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Nov 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 25 2024 |
|
Locked
BMO Capital: Locked ➜ Locked
|
Nov 20 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 19 2024 |
|
Locked
Baird: Locked ➜ Locked
|
Nov 12 2024 |
|
Locked
BMO Capital: Locked ➜ Locked
|
Nov 12 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 12 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Nov 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
